Review on lipegfilgrastim
Maja Gasparic, Sophie LeymanTeva Pharmaceuticals Europe BV, European Headquarters, Amsterdam, the NetherlandsHaving read the original Hoggatt et al article1 and the corrigendum published online on August 27, 2015,2 we do not consider the description of lipegfilgrastim to be entirely accurate, and we...
Guardado en:
Autores principales: | Gasparic M, Leyman S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/71f97796db5a4d8f91a8d2a32e5ba85e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia
por: Hoggatt J, et al.
Publicado: (2015) -
Role of lipegfilgrastim in the management of chemotherapy-induced neutropenia [Corrigendum]
por: Hoggatt J, et al.
Publicado: (2015) -
Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients
por: Guariglia R, et al.
Publicado: (2016) -
Thermosensitive liposomal drug delivery systems: state of the art review
por: Kneidl B, et al.
Publicado: (2014) -
Application of supercritical antisolvent method in drug encapsulation: a review
por: Kalani M, et al.
Publicado: (2011)